UNSPSC 51282928: Marbofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H19FN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X09WU898T, chemically known as 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid but generally known as marbofloxacin, which bears US NIH Compound Identifier 60651. European Medicines Agency schedules Marbofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08648MIG.

UNSPSC 51282928 Marbofloxacin is a Commodity code for a specific veterinary fluoroquinolone antibiotic; however, recent state and local opportunities tagged under this code do not reflect marbofloxacin procurement itself. Instead, the two opportunities posted in 2026 involve related but distinct pharmaceutical and health-safety products: broad-spectrum antibiotics (doxycycline and ciprofloxacin) distributed through state health departments, and naloxone plus drug deactivation systems procured by county health authorities. State and local procurement under this code appears to span state departments of public health and county government health services, typically through piggyback cooperative purchasing vehicles or competitive IFB processes. Purchases target pharmaceutical warehouse supply contracts and public health emergency-response inventory.

The Illinois Department of Public Health awarded a $2.99 million piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for doxycycline and ciprofloxacin tablets across a 12-month initial term with two optional renewal years; Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, and a response deadline of July 26, 2026. Recent activity appears concentrated in Florida and Illinois, with opportunities typically requiring compliance with E-Verify, drug-free workplace certification, and when federally funded (as in the Seminole County case), adherence to federal environmental and procurement regulations. The mismatch between the code's nominal scope (marbofloxacin) and actual recent procurements (human-use antibiotics and naloxone) suggests either miscoding in the state and local databases or that the code is used more broadly to capture antibiotic and related public-health pharmaceutical categories.